[ad_1]
The government of Bangladesh has already signed an agreement with the Seram Institute of India and Beximco Pharmaceuticals Limited to purchase 30 million doses of the Oxford-AstraZeneca vaccine.
Coronavirus: Agreement to import 30 million doses of vaccine from India
Covid-19: what you need to know about the Pfizer vaccine
Covid-19: demand for a 90% effective vaccine
According to a report by The Guardian, the researchers released data on the vaccine’s effectiveness on Monday after the third phase of human testing.
According to the University of Oxford, in the third phase of the trial, analysis of data from two doses of the vaccine showed an efficacy of 90 percent in one and 82 percent in the other.
In other words, the vaccine has been shown to be effective in an average of 80 percent of cases. However, half a dose of vaccine after a full dose can be up to 90 percent effective.
Oxford-AstraZeneca says that experiments have shown that different age groups, even the elderly, can protect themselves from the coronavirus.
Covid-19: after Pfizer, this time Moderner claims it is a 94.5% effective vaccine
Covid-19: This time around, Pfizer’s claim vaccine is 95% effective
Covid-19: Oxford vaccine will arrive in India in ‘April’
“Today we are one step closer to using this vaccine to end the catastrophe that Covid-19 has caused,” said Sarah Gilbert, a professor of vaccines at the University of Oxford.
Incredibly exciting news that the Oxford vaccine has been shown to be so effective in trials. There are still more security checks ahead, but these are fantastic results.
Congratulations to our brilliant scientists at @UniofOxford Y @AstraZeneca, and everyone who volunteered for the trials. https://t.co/84o8TKhQga
– Boris Johnson (@BorisJohnson) November 23, 2020
[ad_2]
